Adma Biologics Stock Performance
| ADMA Stock | USD 19.63 0.42 2.19% |
On a scale of 0 to 100, ADMA Biologics holds a performance score of 3. The firm shows a Beta (market volatility) of 1.6, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ADMA Biologics will likely underperform. Please check ADMA Biologics' standard deviation, treynor ratio, downside variance, as well as the relationship between the total risk alpha and value at risk , to make a quick decision on whether ADMA Biologics' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in ADMA Biologics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, ADMA Biologics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.19 | Five Day Return 0.67 | Year To Date Return 331.43 | Ten Year Return 78.45 | All Time Return 129.59 |
1 | Disposition of 24150 shares by Kestenberg-messina Kaitlin M. of ADMA Biologics at 16.8965 subject to Rule 16b-3 | 09/27/2024 |
2 | Acquisition by Adam Grossman of 870950 shares of ADMA Biologics at 5.4 subject to Rule 16b-3 | 10/04/2024 |
3 | TG Therapeutics Crashes Reversing A Breakout On Its Mixed Third-Quarter Results | 11/04/2024 |
4 | ADMA Biologics Inc earnings beat by 0.03, revenue topped estimates | 11/08/2024 |
5 | Wall Street Analysts See a 31.3 percent Upside in Adma Biologics Can the Stock Really Move This High | 11/18/2024 |
6 | The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions | 11/25/2024 |
7 | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | 11/26/2024 |
8 | Shares of ADMA Biologics, Inc. Advance 36 percent Despite Subdued Growth | 11/27/2024 |
9 | Is Adma Biologics a Buy as Wall Street Analysts Look Optimistic | 12/02/2024 |
10 | Can Adma Biologics Climb 25.5 percent to Reach the Level Wall Street Analysts Expect | 12/04/2024 |
11 | ADMA Biologics, Inc. Shares Purchased by State Street Corp - MarketBeat | 12/11/2024 |
| Begin Period Cash Flow | 86.5 M |
ADMA |
ADMA Biologics Relative Risk vs. Return Landscape
If you would invest 1,809 in ADMA Biologics on September 13, 2024 and sell it today you would earn a total of 154.00 from holding ADMA Biologics or generate 8.51% return on investment over 90 days. ADMA Biologics is currently generating 0.2274% in daily expected returns and assumes 4.4866% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than ADMA, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ADMA Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ADMA Biologics, and traders can use it to determine the average amount a ADMA Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0507
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ADMA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.49 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average ADMA Biologics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADMA Biologics by adding it to a well-diversified portfolio.
ADMA Biologics Fundamentals Growth
ADMA Stock prices reflect investors' perceptions of the future prospects and financial health of ADMA Biologics, and ADMA Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ADMA Stock performance.
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 4.57 B | ||||
| Shares Outstanding | 236.39 M | ||||
| Price To Earning | (1.55) X | ||||
| Price To Book | 19.58 X | ||||
| Price To Sales | 12.12 X | ||||
| Revenue | 258.21 M | ||||
| Gross Profit | 35.27 M | ||||
| EBITDA | 5.12 M | ||||
| Net Income | (28.24 M) | ||||
| Cash And Equivalents | 52.42 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 141.42 M | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 7.94 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | 8.8 M | ||||
| Earnings Per Share | 0.27 X | ||||
| Market Capitalization | 4.64 B | ||||
| Total Asset | 329.18 M | ||||
| Retained Earnings | (506.26 M) | ||||
| Working Capital | 207.21 M | ||||
| Current Asset | 21.29 M | ||||
| Current Liabilities | 4.22 M | ||||
About ADMA Biologics Performance
By analyzing ADMA Biologics' fundamental ratios, stakeholders can gain valuable insights into ADMA Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ADMA Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ADMA Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 372.83 | 298.54 | |
| Return On Tangible Assets | (0.09) | (0.09) | |
| Return On Capital Employed | 0.08 | 0.07 | |
| Return On Assets | (0.09) | (0.09) | |
| Return On Equity | (0.21) | (0.20) |
Things to note about ADMA Biologics performance evaluation
Checking the ongoing alerts about ADMA Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADMA Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ADMA Biologics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 258.21 M. Net Loss for the year was (28.24 M) with profit before overhead, payroll, taxes, and interest of 35.27 M. | |
| ADMA Biologics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ADMA Biologics, Inc. Shares Purchased by State Street Corp - MarketBeat |
- Analyzing ADMA Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ADMA Biologics' stock is overvalued or undervalued compared to its peers.
- Examining ADMA Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ADMA Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ADMA Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ADMA Biologics' stock. These opinions can provide insight into ADMA Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |